-
公开(公告)号：US20100221259A1
公开(公告)日：2010-09-02
申请号：US12776989
申请日：2010-05-10
IPC分类号： A61K39/42 , C07D403/04 , A61K31/55 , A61K31/506 , C07D417/04 , A61K31/541 , C07D413/04 , A61K31/551 , C07D403/14 , A61K31/517 , A61K31/5377 , C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D493/04 , C07F5/02 , A61K31/69 , C07H15/26 , A61K31/7064 , A61K39/00 , A61K31/7072 , A61K31/708 , A61P31/18 , A61P37/02 , A61P29/00 , A61P35/00 , A61P9/00 , A61P3/00
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
公开(公告)号：US20120156219A1
公开(公告)日：2012-06-21
申请号：US13402033
申请日：2012-02-22
IPC分类号： A61K39/42 , A61K31/55 , C07D403/14 , C07D487/04 , A61K31/519 , A61K31/506 , C07D471/04 , C07D417/12 , A61K31/541 , C07D265/36 , A61K31/5365 , A61K31/551 , C07D239/94 , A61K31/517 , C07D223/14 , A61K39/21 , A61P29/00 , A61P37/00 , A61P37/08 , A61P31/00 , A61P31/18 , A61P25/00 , A61P9/00 , A61P3/00 , A61P35/00 , C07D403/04
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
公开(公告)号：US08153625B2
公开(公告)日：2012-04-10
申请号：US12776989
申请日：2010-05-10
IPC分类号： A61K31/55 , C07D403/00
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.).
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。
-
公开(公告)号：US20070167459A1
公开(公告)日：2007-07-19
申请号：US10538758
申请日：2003-12-09
IPC分类号： A61K31/519 , A61K31/517 , C07D403/02
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
公开(公告)号：US07759336B2
公开(公告)日：2010-07-20
申请号：US10538758
申请日：2003-12-09
IPC分类号： A01N43/00 , A61K31/55 , C07D223/00
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
-
-
-
搜索结果
5 条记录 (耗时 0.036 秒)
